Pioneer in Autoimmune CAR T Treatments

Our development operations are focused on creative and efficient paths to bring innovative and cost-effective therapies to patients with unmet medical needs. First mover-clinical trials are ongoing, supported by our U.S.- and China-based research & development organization. iCell has expertise in both designing and manufacturing cell therapies. iCell makes all viral vectors in-house, and our state-of-the-art GMP facility in China enables the manufacturing of our cell therapies reliably and cost effectively worldwide.

iCell possesses extensive intellectual property world-wide for innovative and proprietary cell therapies including multiple patents for dual CARs (both design and armoring) including a BCMA CD19 compound CAR (cCAR) for autoimmune conditions. cCAR targets the “root cause” of disease, the B cell and plasma/long-lived plasma cells.

iCell’s cCAR has successfully treated both lymphoma and autoimmune diseases  We are the first in the world to introduce a CAR therapy to treat lupus. iCell’s cCAR has achieved durable medication and symptom free remission from lupus [in patients] for over 4.5 years. As of today iCell has accumulated the largest available public database of the clinical use of CARs in patients with autoimmune diseases. iCell leverages this database to accelerate clinical development of its proprietary CAR treatments in lupus and other autoimmune diseases.

iCell’s expansive intellectual property portfolio, exceptional science, research and product development, manufacturing expertise, global partnerships, as well as clinical experience provide for a strong foundation to deliver novel products to market.

Pioneer in treating AML

iCell’s first in the world, anti-CD33 and anti-CLL1 compound CAR, has demonstrated remarkable efficacy in treating AML. This approach targets both the bulk of disease and leukemic stem cells.